Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17937846 | 0.82 | HTR2A (0.33) | ALDH1A1MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17937647 | 0.82 | AOC3 (0.39) | LMNASMN1; SMN2MAPTTDP1 | |
| SCHEMBL705765 | 0.82 | LMNA (0.43) | LMNATDP1MEN1KMT2A | |
| SCHEMBL6683460 | 0.78 | ALDH1A1 (0.38) | CHRNA7ALDH1A1 | |
| SCHEMBL3152929 | 0.75 | CHRNA7 (0.37) | CHRNA7ALDH1A1LMNASMN1; SMN2ACHE | |
| SCHEMBL17937710 | 0.69 | IDO1 (0.39) | ALDH1A1MAPTCYP3A4CYP2D6 | |
| SCHEMBL17937563 | 0.69 | AOC3 (0.44) | LMNAMEN1KMT2A | |
| SCHEMBL8750362 | 0.68 | AOC3 (0.39) | CHRNA7ALDH1A1LMNASMN1; SMN2ACHE | |
| SCHEMBL17937839 | 0.68 | KMT2A (0.33) | ALDH1A1SMN1; SMN2MEN1CYP1A2CYP3A4 | |
| SCHEMBL17937806 | 0.68 | IDO1 (0.37) | LMNASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1782436-B1 | METHOD FOR TREATING ELECTRICAL CABLE AT SUSTAINED ELEVATED PRESSURE | NOVINIUM INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-7615247-B2 | Promoting transport of dielectric enhancing fluid into polymeric insulation; utilizing residual injection pressure to expand interstitial void volume along entire length of treatment segment | NOVINIUM, INC. (US) | 2009-11-10 | — | — | US | claimed |
| EP-1782436-A2 | METHOD FOR TREATING ELECTRICAL CABLE AT SUSTAINED ELEVATED PRESSURE | Novinium, Inc. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2005084321-A2 | METHOD FOR TREATING ELECTRICAL CABLE AT SUSTAINED ELEVATED PRESSURE | NOVINIUM, INC. (US) | 2005-09-15 | — | — | WO | claimed |
| US-12516079-B2 | Silane functional stabilizers for extending long-term electrical power cable performance | SOUTHWIRE COMPANY, LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240254154-A1 | SILANE FUNCTIONAL STABILIZERS FOR EXTENDING LONG-TERM ELECTRICAL POWER CABLE PERFORMANCE | SOUTHWIRE COMPANY, LLC | 2024-08-01 | — | — | US | disclosed |
| EP-1782436-B1 | METHOD FOR TREATING ELECTRICAL CABLE AT SUSTAINED ELEVATED PRESSURE | NOVINIUM INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-8656586-B2 | Method for treating electrical cable at sustained elevated pressure | NOVINIUM, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8572842-B2 | Method for thermally enhancing injection of power cables | NOVINIUM, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-1744866-B1 | METHOD FOR SELECTING FORMULATIONS TO TREAT ELECTRICAL CABLES | NOVINIUM INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8205326-B2 | Method for treating electrical cable at sustained elevated pressure | NOVINIUM, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120102729-A1 | METHOD FOR TREATING ELECTRICAL CABLE AT SUSTAINED ELEVATED PRESSURE | NOVINIUM, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-7353601-B1 | Integrated method for restoring electrical power cable | NOVINIUM, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1782436-A2 | METHOD FOR TREATING ELECTRICAL CABLE AT SUSTAINED ELEVATED PRESSURE | Novinium, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007027826-A2 | METHOD FOR EXTENDING LONG-TERM ELECTRICAL POWER CABLE PERFORMANCE | NOVINIUM, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1744866-A2 | METHOD FOR SELECTING FORMULATIONS TO TREAT ELECTRICAL CABLES | Novinium, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005084321-A2 | METHOD FOR TREATING ELECTRICAL CABLE AT SUSTAINED ELEVATED PRESSURE | NOVINIUM, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005084322-A2 | METHOD FOR SELECTING FORMULATIONS TO TREAT ELECTRICAL CABLES | NOVINIUM, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050192708-A1 | Method for selecting formulations to treat electrical cables | NOVINIUM, INC. (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050189130-A1 | Method for treating electrical cable at sustained elevated pressure | NOVINIUM, INC. (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254154-A1 | SILANE FUNCTIONAL STABILIZERS FOR EXTENDING LONG-TERM ELECTRICAL POWER CABLE PERFORMANCE | SMC1A, ITGA1, CABLES1 | CHRNA7 2742/4885ALDH1A1 80/4885LMNA 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.